Advertisement
UK markets closed
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • FTSE 250

    19,884.73
    +74.07 (+0.37%)
     
  • AIM

    743.26
    +1.15 (+0.15%)
     
  • GBP/EUR

    1.1712
    +0.0018 (+0.16%)
     
  • GBP/USD

    1.2621
    -0.0001 (-0.01%)
     
  • Bitcoin GBP

    55,666.34
    +323.82 (+0.59%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • NIKKEI 225

    40,337.05
    +168.98 (+0.42%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • CAC 40

    8,205.81
    +1.00 (+0.01%)
     

Exploring the Growth Trajectory of Amgen’s Repatha

Exploring the Growth Trajectory of Amgen’s Repatha

Amgen (AMGN) is one of the world’s leading biotechnology companies, with a presence in ~100 countries. Amgen’s Repatha is a human monoclonal antibody that inhibits proprotein convertase kexin type nine (or PCSK9). The drug has been approved in more than 50 regions, including the United States, Japan, Canada, and the European Union.